Literature DB >> 28733219

Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study.

Philippe Kolly1, Oliver Waidmann2, Johannes Vermehren2, Christophe Moreno3, Isabelle Vögeli4, Thomas Berg5, David Semela6, Stefan Zeuzem2, Jean-François Dufour7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28733219     DOI： 10.1016/j.jhep.2017.07.007

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  18 in total

1.  Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy.

Authors:  N Saraiya; A C Yopp; N E Rich; M Odewole; N D Parikh; A G Singal
Journal:  Aliment Pharmacol Ther       Date:  2018-05-30       Impact factor: 8.171

2.  Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents.

Authors:  Winnie Y Zou; Kati Choi; Jennifer R Kramer; Xian Yu; Yumei Cao; Hashem B El-Serag; Fasiha Kanwal
Journal:  Dig Dis Sci       Date:  2019-04-30       Impact factor: 3.199

Review 3.  AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.

Authors:  Amit G Singal; Joseph K Lim; Fasiha Kanwal
Journal:  Gastroenterology       Date:  2019-03-13       Impact factor: 22.682

4.  Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.

Authors:  Amit G Singal; Nicole E Rich; Neil Mehta; Andrea Branch; Anjana Pillai; Maarouf Hoteit; Michael Volk; Mobolaji Odewole; Steven Scaglione; Jennifer Guy; Adnan Said; Jordan J Feld; Binu V John; Catherine Frenette; Parvez Mantry; Amol S Rangnekar; Omobonike Oloruntoba; Michael Leise; Janice H Jou; Kalyan Ram Bhamidimarri; Laura Kulik; Tram Tran; Hrishikesh Samant; Renumathy Dhanasekaran; Andres Duarte-Rojo; Reena Salgia; Sheila Eswaran; Prasun Jalal; Avegail Flores; Sanjaya K Satapathy; Robert Wong; Annsa Huang; Suresh Misra; Myron Schwartz; Robert Mitrani; Sasank Nakka; Wassim Noureddine; Chanda Ho; Venkata R Konjeti; Alexander Dao; Kevin Nelson; Kelly Delarosa; Usman Rahim; Meher Mavuram; Jesse J Xie; Caitlin C Murphy; Neehar D Parikh
Journal:  Gastroenterology       Date:  2019-01-18       Impact factor: 22.682

5.  The impact of direct-acting antiviral therapy for hepatitis C on hepatocellular carcinoma risk.

Authors:  Feng Su; George N Ioannou
Journal:  Curr Hepatol Rep       Date:  2018-09-20

6.  Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals.

Authors:  Fabian Finkelmeier; Georg Dultz; Kai-Henrik Peiffer; Bernd Kronenberger; Franziska Krauss; Stefan Zeuzem; Christoph Sarrazin; Johannes Vermehren; Oliver Waidmann
Journal:  Liver Cancer       Date:  2018-03-01       Impact factor: 11.740

7.  Hepatocellular carcinoma recurrence after directly acting antivirals for chronic hepatitis C: a 2-year follow-up study.

Authors:  Ahmed Kamal; Amr Aly Abd Elmoety; Yousri Abdelmeguid Rostom; Mohamed Said Shater; Sameh Aldesoky Lashen
Journal:  Clin Exp Hepatol       Date:  2021-03-11

Review 8.  Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy.

Authors:  Francesco Negro
Journal:  Cold Spring Harb Perspect Med       Date:  2020-04-01       Impact factor: 6.915

9.  Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Sonal Singh; Amit Nautiyal; Yoon K Loke
Journal:  Frontline Gastroenterol       Date:  2018-07-30

10.  Impact of hepatitis C treatment on long-term outcomes for patients with hepatocellular carcinoma: a United States Safety Net Collaborative Study.

Authors:  Michael K Turgeon; Rachel M Lee; Adriana C Gamboa; Adam Yopp; Emily L Ryon; Neha Goel; Annie Wang; Ann Y Lee; Sommer Luu; Cary Hsu; Eric Silberfein; Shishir K Maithel; Maria C Russell
Journal:  HPB (Oxford)       Date:  2020-08-07       Impact factor: 3.647
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.